Delvys Rodríguez‐Abreu

Universidad de Las Palmas de Gran Canaria

Also affiliated with Hospital Universitario Insular de Gran Canaria, Spanish Ovarian Cancer Research Group, GEICAM – Spanish Breast Cancer Group

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer”.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2302983

N/A

7.3DataRank · unranked

1056 citations

Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao +14 more

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2

N/A

3.7DataRank · unranked

262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine(2016)10.1056/nejmoa1606774

N/A

1.4DataRank · unranked

9979 citations

Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp +16 more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine(2018)10.1056/nejmoa1801005

N/A

1.3DataRank · unranked

6524 citations

Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis +34 more

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of Clinical Oncology(2021)10.1200/jco.20.03579

N/A

0.832DataRank · unranked

256 citations

Mehmet A. N. Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, Irfan Çiçin +15 more

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Journal of Clinical Oncology(2023)10.1200/jco.22.02561

N/A

0.708DataRank · unranked

111 citations

Delvys Rodríguez‐Abreu, Marta Simó, Bartomeu Massutí, Óscar Juan, Gerardo Huidobro +13 more

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer(2020)10.1002/cncr.33142

N/A

0DataRank · unranked

111 citations

Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino +8 more